immunoprobe
panitumumab
drozitumab
lexatumumab
tisotumab
heterophile
acrixolimab
agonistic monoclonal antibody
elotuzumab
fontolizumab
pamrevlumab
sonepcizumab
intrabody
tucotuzumab
-toxa-
Ab
bivatuzumab
lintuzumab
matuzumab
samalizumab
tabalumab
caplacizumab
carlumab
glembatumumab
antiantibody
antipolyvalent
immunocharacterize
immunopanning
intetumumab
onartuzumab
evolocumab
amlitelimab
nofetumomab
ozoralizumab
cibisatamab
antiustekinumab
ozogamicin
polyclonal
zanolimumab
ramucirumab
reagin
adecatumumab
cixutumumab
antisubstance
antiphospholipid
antisynthetase
antigenomic
presentation
autocentromere
volociximab